Join to View Full Profile
10 Center Drive10/Room 12n226Bethesda, MD 20892
Dr. Karzai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Fatima Karzai is an oncologist located in Bethesda, MD, specializing in prostate cancer. She earned her medical degree from George Washington University School of Medicine and Health Sciences. Dr. Karzai has authored multiple publications focused on prostate cancer, including articles on gene signatures, prostate-specific membrane antigen imaging, and stem cell dynamics in castrate-resistant prostate cancer. Her research has contributed to journals such as Translational Andrology and Urology, Journal of Clinical Oncology, and European Urology Oncology. She is involved in clinical trials, actively serving as the principal investigator examining genomics, imaging, and therapeutic strategies in prostate cancer.
Education & Training
George Washington University School of Medicine and Health SciencesClass of 2005
Certifications & Licensure
MD State Medical License 2009 - 2026
DC State Medical License 2005 - 2009
VA State Medical License 2005 - 2009
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Roles: Contact, Principal Investigator
- Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Roles: Principal Investigator, Contact
- Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio
Journal of Clinical Oncology. 2025-12-01 - 1 citationsLocalized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition.Scott Wilkinson, Anson T Ku, Rosina T Lis, Isaiah M King, Daniel Low
The Journal of Clinical Investigation. 2025-11-17 - Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.Braden Millan, Nikhil Pramod, Ruben Blachman-Braun, Jaskirat Saini, Lauren Loebach
The Prostate. 2025-11-16
Journal Articles
- Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy MeetingThomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Press Mentions
Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended Treatments, Study FindsFebruary 18th, 2025
Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
